New therapies are needed for patients with Hodgkin or non-Hodgkin lymphomas that are
resistant to standard therapies. Indeed, unresponsiveness to standard chemotherapy and …

Lymphomas are solid tumours of the immune system. Hodgkin's lymphoma accounts for
about 10% of all lymphomas, and the remaining 90% are referred to as non-Hodgkin …

PURPOSE Chimeric antigen receptor (CAR) T-cell therapy of B-cell malignancies has
proved to be effective. We show how the same approach of CAR T cells specific for CD30 …

Chimeric antigen receptor T cell (CAR-T cell) therapy is a novel adoptive immunotherapy
where T lymphocytes are engineered with synthetic receptors known as chimeric antigen …

A comment on this article appears in" Algorithm for immunophenotyping of low-grade B
lymphomas." Blood. 1996 Sep 15; 88 (6): 2361-2. A comment on this article appears in" …

CD30 is a member of the tumor necrosis factor receptor superfamily. It is characteristically
expressed in certain hematopoietic malignancies, including anaplastic large cell lymphoma …

Purpose: An antibody-drug conjugate consisting of monomethyl auristatin E (MMAE)
conjugated to the anti-CD30 monoclonal antibody (mAb) cAC10, with eight drug moieties …

Abstract The International Peripheral T-Cell Lymphoma Project is a collaborative effort
designed to gain better understanding of peripheral T-cell and natural killer (NK)/T-cell …

Tyrosine kinases are involved in the pathogenesis of most cancers. However, few tyrosine
kinases have been shown to have a well-defined pathogenetic role in lymphomas. The …

Systemic anaplastic large cell lymphoma (ALCL) is an aggressive CD30+ non-Hodgkin
lymphoma. Anaplastic lymphoma kinase–positive (ALK+) ALCL is associated with the NPM …